Esperion Therapeutics (NASDAQ:ESPR) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biopharmaceutical company’s stock.

ESPR has been the subject of a number of other reports. StockNews.com downgraded Esperion Therapeutics from a buy rating to a hold rating in a report on Friday, September 27th. Needham & Company LLC lowered their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a research note on Tuesday, August 13th. Finally, Bank of America downgraded shares of Esperion Therapeutics from a neutral rating to an underperform rating and reduced their price target for the stock from $2.90 to $2.50 in a research report on Thursday, June 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Esperion Therapeutics has a consensus rating of Hold and a consensus price target of $8.17.

Esperion Therapeutics Price Performance

Shares of ESPR stock opened at $2.16 on Wednesday. The firm has a fifty day moving average of $1.84 and a two-hundred day moving average of $2.19. The firm has a market cap of $409.23 million, a P/E ratio of -2.18 and a beta of 1.00. Esperion Therapeutics has a 1-year low of $0.70 and a 1-year high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million during the quarter, compared to analyst estimates of $51.90 million. On average, sell-side analysts expect that Esperion Therapeutics will post -0.04 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BOKF NA bought a new stake in Esperion Therapeutics in the second quarter valued at $26,000. Xponance Inc. acquired a new position in shares of Esperion Therapeutics during the second quarter valued at $28,000. CVI Holdings LLC bought a new stake in shares of Esperion Therapeutics during the first quarter valued at about $37,000. State Board of Administration of Florida Retirement System acquired a new stake in Esperion Therapeutics in the first quarter worth about $50,000. Finally, National Bank of Canada FI grew its position in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 10,225 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.